Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
SOMERSET, NJ–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company that develops, manufactures and markets novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board of Directors: Mr. Tomas Heyman as Class I Director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II Director of Legend Biotech, and Dr. Li Mao as Class III Director of Legend Biotech. Mr. Heyman and Dr. Mao have been identified by the Board as meeting the independence requirements of The Nasdaq Stock Market LLC listing rules. Ms. Ye “Sally” Wang has also resigned as Chair, effective August 2, 2022, but will remain on the Board as a director and in her committee assignments. Dr. Frank Zhang, one of the newly appointed directors, was elected chairman of the board.
“The size and composition of the board of directors has been under review for some time. After a thorough review, the Board of Directors concluded that Mr. Heyman, Dr. Zhang and Dr. Mao possessed the essential skills and experience to help execute the company’s long-term strategy and advance our goals. said Ying Huang, Ph.D., Chairman and CEO of Legend Biotech. Dr. Huang continued, “I would like to thank Ms. Wang for her dedication, leadership and valuable insights as President. We look forward to her many future contributions as she remains an important asset to our Board. »
About Tomas J. Heyman
Mr. Heyman previously served as Chairman of Johnson & Johnson’s Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a global healthcare company from 2015 to September 2019 and as Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from 1992 to 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceutical NV, a pharmaceutical company, from 2008 to 2016. Mr. Heyman served as a director of OptiNose, Inc., a specialty pharmaceutical, since December 2020, director of Akero Therapeutics, Inc., a biotechnology company, since June 2020 and director of Adagio Therapeutics Inc., a biopharmaceutical company, since June 2021. Mr. Heyman holds a master’s degree in law from KU Leuven in Belgium. He pursued postgraduate studies in international law in Geneva, Switzerland, and postgraduate studies in business management at the University of Antwerp in Belgium.
About Dr Frank Zhang
Dr. Zhang has been a Non-Executive Director of GenScript Biotech Corporation (“GenScript”) since May 2022 and prior to that, he served as Chairman and Chief Executive Officer of GenScript from 2015 to 2020. He co-founded the GenScript Group in 2002 and served as Director of various group companies before GenScript became the holding company for the group companies following the corporate reorganization for GenScript’s IPO in 2015. In 2015, Dr. Zhang founded the company as a subsidiary of GenScript, developing GenScript’s business objective is to research, manufacture and market a wide range of immunotherapy treatments. Dr. Zhang served as Chairman of the Company’s Board of Directors from 2015 to November 2020 and served as the Company’s Chief Executive Officer from August 2020 to September 2020. In 2018, Dr. Zhang was named Person of the Year at the China Healthcare Summit in recognition of its contribution and significant impact in the field of healthcare. Dr. Zhang is also the author of more than 20 articles published in peer-reviewed journals and is the inventor of 9 scientific patents. Prior to founding GenScript, Dr. Zhang worked as a Principal Investigator at Schering-Plough from 1995 to 2002 where he received his Presidential Award. Dr. Zhang holds a Ph.D. in biochemistry from Duke University, a master’s degree from Nanjing University and a bachelor’s degree from the Chengdu Institute of Geology.
About Dr Li Mao
Dr. Mao is currently Medical Director of SciClone Pharmaceuticals, Inc., a position he has held since June 2022. Previously, Dr. Mao served as Medical Director of Sino Biopharmaceutical Co., Ltd. from May 2021 to June. 2022, Managing Director of Livzonbio from March 2021 to April 2021 and Managing Director of Xcovery Holdings, Inc. from November 2018 to March 2021. Dr. Mao also served as Senior Vice President and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. from March 2018 to March 2021 and Vice Chairman of Johnson & Johnson from June 2016 to February 2018. Additionally, he was a Professor at MD Anderson Cancer Center from 2004 to March 2009 and a Professor at the University of Maryland, Baltimore from March 2009 to June 2016. Dr. Mao also served as a board member of Betta Pharmaceuticals Co., Ltd, which is listed on the Shenzhen Stock Exchange, from April 2018 to March 2021. Dr. Mao holds a Gold doctor’s degree from Nanjing Medical University. Dr. Mao also completed a postdoctoral fellowship in cancer genetics at Johns Hopkins University School of Medicine.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Based in Somerset, New Jersey, we develop advanced cell therapies across a wide range of technology platforms, including autologous and allogeneic chimeric antigen receptor T cells and natural killer (NK) cell-based immunotherapies . From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, effective and cutting-edge therapies for patients around the world.
Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.